Northland Securities Forecasts Nephros Q2 Earnings

Nephros Inc. (NASDAQ:NEPH) – Equities research analysts at Northland Securities issued their Q2 2026 earnings per share estimates for shares of Nephros in a research report issued to clients and investors on Friday, July 17th. Northland Securities analyst B. Brooks forecasts that the company will earn $0.01 per share for the quarter. Northland Securities has a “Market Perform” rating and a $4.00 price objective on the stock. The consensus estimate for Nephros’ current full-year earnings is $0.03 per share. Northland Securities also issued estimates for Nephros’ Q3 2026 earnings at $0.01 EPS, Q4 2026 earnings at $0.00 EPS, FY2026 earnings at $0.03 EPS, Q1 2027 earnings at $0.03 EPS, Q2 2027 earnings at $0.05 EPS, Q3 2027 earnings at $0.06 EPS, Q4 2027 earnings at $0.06 EPS and FY2027 earnings at $0.19 EPS.

Nephros (NASDAQ:NEPH) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, meeting analysts’ consensus estimates of $0.01. The company had revenue of $5.21 million for the quarter, compared to analyst estimates of $5.02 million. Nephros had a return on equity of 7.66% and a net margin of 4.06%.

Several other equities research analysts have also recently commented on NEPH. Zacks Research upgraded Nephros to a “hold” rating in a research note on Monday. Weiss Ratings downgraded shares of Nephros from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Nephros currently has an average rating of “Hold” and an average price target of $5.00.

Nephros Stock Performance

NASDAQ:NEPH opened at $3.65 on Tuesday. The stock has a 50-day simple moving average of $3.47 and a 200 day simple moving average of $3.62. Nephros has a 52-week low of $2.66 and a 52-week high of $6.42. The company has a market cap of $39.64 million, a PE ratio of 52.15 and a beta of 1.49.

Hedge Funds Weigh In On Nephros

Several hedge funds have recently modified their holdings of the stock. Kestra Advisory Services LLC bought a new stake in Nephros during the fourth quarter worth about $29,000. Dimensional Fund Advisors LP grew its stake in Nephros by 52.5% in the first quarter. Dimensional Fund Advisors LP now owns 20,745 shares of the company’s stock valued at $62,000 after purchasing an additional 7,144 shares in the last quarter. Heron Bay Capital Management acquired a new position in shares of Nephros during the 4th quarter worth approximately $66,000. Citadel Advisors LLC increased its position in shares of Nephros by 39.2% during the 3rd quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after purchasing an additional 4,655 shares during the last quarter. Finally, XTX Topco Ltd raised its stake in shares of Nephros by 48.5% during the 4th quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock worth $105,000 after purchasing an additional 7,062 shares in the last quarter. Institutional investors own 41.10% of the company’s stock.

Key Stories Impacting Nephros

Here are the key news stories impacting Nephros this week:

• Positive Sentiment: Zacks Research upgraded Nephros to Hold, which can be seen as a modestly improved view on the stock and may help support sentiment. Tickerreport.com
• Neutral Sentiment: Northland Securities reiterated a Market Perform rating and $4.00 price target, suggesting the firm sees limited near-term upside or downside from current levels. The note also laid out earnings estimates calling for small profits in 2026 and stronger earnings growth in 2027.
• Neutral Sentiment: The company’s latest earnings report was roughly in line with expectations, with Q1 EPS of $0.01 and revenue of $5.21 million topping estimates slightly, which supports the view that Nephros is executing steadily but not delivering a major surprise.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.